|
1
|
Kagan HM and Trackman PC: Properties and
function of lysyl oxidase. Am J Respir Cell Mol Biol. 5:206–210.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Smith-Mungo LI and Kagan HM: Lysyl
oxidase: properties, regulation and multiple functions in biology.
Matrix Biol. 16:387–398. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lopez KM and Greenaway FT: Identification
of the copper-binding ligands of lysyl oxidase. J Neural Transm.
118:1101–1109. 2011. View Article : Google Scholar
|
|
4
|
Lucero HA and Kagan HM: Lysyl oxidase: an
oxidative enzyme and effector of cell function. Cell Mol Life Sci.
63:2304–2316. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hohenester E, Sasaki T and Timpl R:
Crystal structure of a scavenger receptor cysteine-rich domain
sheds light on an ancient superfamily. Nat Struct Biol. 6:228–232.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Martínez VG, Moestrup SK, Holmskov U,
Mollenhauer J and Lozano F: The conserved scavenger receptor
cysteine-rich super-family in therapy and diagnosis. Pharmacol Rev.
63:967–1000. 2011. View Article : Google Scholar
|
|
7
|
Payne SL, Hendrix MJ and Kirschmann DA:
Paradoxical roles for lysyl oxidases in cancer - a prospect. J Cell
Biochem. 101:1338–1354. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Barker HE, Cox TR and Erler JT: The
rationale for targeting the LOX family in cancer. Nat Rev Cancer.
12:540–552. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Saito H, Papaconstantinou J, Sato H and
Goldstein S: Regulation of a novel gene encoding a lysyl
oxidase-related protein in cellular adhesion and senescence. J Biol
Chem. 272:8157–8160. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zuber J, Tchernitsa OI, Hinzmann B,
Schmitz AC, Grips M, Hellriegel M, Sers C, Rosenthal A and Schäfer
R: A genome-wide survey of RAS transformation targets. Nat Genet.
24:144–152. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rost T, Pyritz V, Rathcke IO, Görögh T,
Dünne AA and Werner JA: Reduction of LOX- and LOXL2-mRNA expression
in head and neck squamous cell carcinomas. Anticancer Res. 23(2B):
1565–1573. 2003.PubMed/NCBI
|
|
12
|
Hough CD, Sherman-Baust CA, Pizer ES,
Montz FJ, Im DD, Rosenshein NB, Cho KR, Riggins GJ and Morin PJ:
Large-scale serial analysis of gene expression reveals genes
differentially expressed in ovarian cancer. Cancer Res.
60:6281–6287. 2000.PubMed/NCBI
|
|
13
|
Ono K, Tanaka T, Tsunoda T, Kitahara O,
Kihara C, Okamoto A, Ochiai K, Takagi T and Nakamura Y:
Identification by cDNA microarray of genes involved in ovarian
carcinogenesis. Cancer Res. 60:5007–5011. 2000.PubMed/NCBI
|
|
14
|
Zhan P, Shen XK, Qian Q, Zhu JP, Zhang Y,
Xie HY, Xu CH, Hao KK, Hu W, Xia N, et al: Down-regulation of lysyl
oxidase-like 2 (LOXL2) is associated with disease progression in
lung adenocarcinomas. Med Oncol. 29:648–655. 2012. View Article : Google Scholar
|
|
15
|
Barker HE, Chang J, Cox TR, Lang G, Bird
D, Nicolau M, Evans HR, Gartland A and Erler JT: LOXL2-mediated
matrix remodeling in metastasis and mammary gland involution.
Cancer Res. 71:1561–1572. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fong SF, Dietzsch E, Fong KS, Hollosi P,
Asuncion L, He Q, Parker MI and Csiszar K: Lysyl oxidase-like 2
expression is increased in colon and esophageal tumors and
associated with less differentiated colon tumors. Genes Chromosomes
Cancer. 46:644–655. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rückert F, Joensson P, Saeger HD,
Grützmann R and Pilarsky C: Functional analysis of LOXL2 in
pancreatic carcinoma. Int J Colorectal Dis. 25:303–311. 2010.
View Article : Google Scholar
|
|
18
|
Peng L, Ran YL, Hu H, Yu L, Liu Q, Zhou Z,
Sun YM, Sun LC, Pan J, Sun LX, et al: Secreted LOXL2 is a novel
therapeutic target that promotes gastric cancer metastasis via the
Src/FAK pathway. Carcinogenesis. 30:1660–1669. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cano A, Santamaría PG and Moreno-Bueno G:
LOXL2 in epithelial cell plasticity and tumor progression. Future
Oncol. 8:1095–1108. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ahn SG, Dong SM, Oshima A, Kim WH, Lee HM,
Lee SA, Kwon SH, Lee JH, Lee JM, Jeong J, et al: LOXL2 expression
is associated with invasiveness and negatively influences survival
in breast cancer patients. Breast Cancer Res Treat. 141:89–99.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wong CC, Tse AP, Huang YP, Zhu YT, Chiu
DK, Lai RK, Au SL, Kai AK, Lee JM, Wei LL, et al: Lysyl
oxidase-like 2 is critical to tumor microenvironment and metastatic
niche formation in hepatocellular carcinoma. Hepatology.
60:1645–1658. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Akiri G, Sabo E, Dafni H, Vadasz Z,
Kartvelishvily Y, Gan N, Kessler O, Cohen T, Resnick M, Neeman M
and Neufeld G: Lysyl oxidase-related protein-1 promotes tumor
fibrosis and tumor progression in vivo. Cancer Res. 63:1657–1666.
2003.PubMed/NCBI
|
|
23
|
Brekhman V and Neufeld G: A novel
asymmetric 3D in-vitro assay for the study of tumor cell invasion.
BMC Cancer. 9:4152009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cox TR and Erler JT: Remodeling and
homeostasis of the extracellular matrix: Implications for fibrotic
diseases and cancer. Dis Model Mech. 4:165–178. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mäki JM, Räsänen J, Tikkanen H, Sormunen
R, Makikallio K, Kivirikko KI and Soininen R: Inactivation of the
lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular
dysfunction, and perinatal death in mice. Circulation.
106:2503–2509. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mäki JM, Sormunen R, Lippo S,
Kaarteenaho-Wiik R, Soininen R and Myllyharju J: Lysyl oxidase is
essential for normal development and function of the respiratory
system and for the integrity of elastic and collagen fibers in
various tissues. Am J Pathol. 167:927–936. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu X, Zhao Y, Gao J, Pawlyk B, Starcher
B, Spencer JA, Yanagisawa H, Zuo J and Li T: Elastic fiber
homeostasis requires lysyl oxidase-like 1 protein. Nat Genet.
36:178–182. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mäki JM: Lysyl oxidases in mammalian
development and certain pathological conditions. Histol
Histopathol. 24:651–660. 2009.PubMed/NCBI
|
|
29
|
Vadasz Z, Kessler O, Akiri G,
Gengrinovitch S, Kagan HM, Baruch Y, Izhak OB and Neufeld G:
Abnormal deposition of collagen around hepatocytes in Wilson's
disease is associated with hepatocyte specific expression of lysyl
oxidase and lysyl oxidase like protein-2. J Hepatol. 43:499–507.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nieto MA: The ins and outs of the
epithelial to mesenchymal transition in health and disease. Annu
Rev Cell Dev Biol. 27:347–376. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Barry-Hamilton V, Spangler R, Marshall D,
McCauley S, Rodriguez HM, Oyasu M, Mikels A, Vaysberg M, Ghermazien
H, Wai C, et al: Allosteric inhibition of lysyl oxidase-like-2
impedes the development of a pathologic microenvironment. Nat Med.
16:1009–1017. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Peinado H, Moreno-Bueno G, Hardisson D,
Pérez-Gómez E, Santos V, Mendiola M, de Diego JI, Nistal M,
Quintanilla M, Portillo F and Cano A: Lysyl oxidase-like 2 as a new
poor prognosis marker of squamous cell carcinomas. Cancer Res.
68:4541–4550. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Offenberg H, Brünner N, Mansilla F,
Orntoft Torben F and Birkenkamp-Demtroder K: TIMP-1 expression in
human colorectal cancer is associated with TGF-B1, LOXL2, INHBA1,
TNF-AIP6 and TIMP-2 transcript profiles. Mol Oncol. 2:233–240.
2008. View Article : Google Scholar
|
|
34
|
Moreno-Bueno G, Salvador F, Martín A,
Floristán A, Cuevas EP, Santos V, Montes A, Morales S, Castilla MA,
Rojo-Sebastián A, et al: Lysyl oxidase-like 2 (LOXL2), a new
regulator of cell polarity required for metastatic dissemination of
basal-like breast carcinomas. EMBO Mol Med. 3:528–544. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Baker AM, Cox TR, Bird D, Lang G, Murray
GI, Sun XF, Southall SM, Wilson JR and Erler JT: The role of lysyl
oxidase in SRC-dependent proliferation and metastasis of colorectal
cancer. J Natl Cancer Inst. 103:407–424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Baker AM, Bird D, Lang G, Cox TR and Erler
JT: Lysyl oxidase enzymatic function increases stiffness to drive
colorectal cancer progression through FAK. Oncogene. 32:1863–1868.
2013. View Article : Google Scholar
|
|
37
|
Ferrara N and Kerbel RS: Angiogenesis as a
therapeutic target. Nature. 438:967–974. PubMed/NCBI
|
|
38
|
Kerbel RS: Tumor angiogenesis. N Engl J
Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jubb AM and Harris AL: Biomarkers to
predict the clinical efficacy of bevacizumab in cancer. Lancet
Oncol. 11:1172–1183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kerbel R and Folkman J: Clinical
translation of angiogenesis inhibitors. Nat Rev Cancer. 2:727–739.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
41
|
Baker AM, Bird D, Welti JC, Gourlaouen M,
Lang G, Murray GI, Reynolds AR, Cox TR and Erler JT: Lysyl oxidase
plays a critical role in endothelial cell stimulation to drive
tumor angiogenesis. Cancer Res. 73:583–594. 2013. View Article : Google Scholar :
|
|
42
|
Zaffryar-Eilot S, Marshall D, Voloshin T,
Bar-Zion A, Spangler R, Kessler O, Ghermazien H, Brekhman V,
Suss-Toby E, Adam D, et al: Lysyl oxidase-like-2 promotes tumour
angiogenesis and is a potential therapeutic target in angiogenic
tumours. Carcinogenesis. 34:2370–2379. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cassavaugh J and Lounsbury KM:
Hypoxia-mediated biological control. J Cell Biochem. 112:735–744.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang GL, Jiang BH, Rue EA and Semenza GL:
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS
heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci
USA. 92:5510–5514. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Postovit LM, Abbott DE, Payne SL, Wheaton
WW, Margaryan NV, Sullivan R, Jansen MK, Csiszar K, Hendrix MJ and
Kirschmann DA: Hypoxia/reoxygenation: A dynamic regulator of lysyl
oxidase-facilitated breast cancer migration. J Cell Biochem.
103:1369–1378. 2008. View Article : Google Scholar
|
|
46
|
Schietke R, Warnecke C, Wacker I, Schödel
J, Mole DR, Campean V, Amann K, Goppelt-Struebe M, Behrens J,
Eckardt KU and Wiesener MS: The lysyl oxidases LOX and LOXL2 are
necessary and sufficient to repress E-cadherin in hypoxia: insights
into cellular transformation processes mediated by HIF-1. J Biol
Chem. 285:6658–6669. 2010. View Article : Google Scholar :
|
|
47
|
Pez F, Dayan F, Durivault J, Kaniewski B,
Aimond G, Le Provost GS, Deux B, Clézardin P, Sommer P, Pouysségur
J and Reynaud C: The HIF-1-inducible lysyl oxidase activates HIF-1
via the Akt pathway in a positive regulation loop and synergizes
with HIF-1 in promoting tumor cell growth. Cancer Res.
71:1647–1657. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bignon M, Pichol-Thievend C, Hardouin J,
Malbouyres M, Bréchot N, Nasciutti L, Barret A, Teillon J, Guillon
E, Etienne E, et al: Lysyl oxidase-like protein-2 regulates
sprouting angiogenesis and type IV collagen assembly in the
endothelial basement membrane. Blood. 118:3979–3989. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Payne SL, Fogelgren B, Hess AR, Seftor EA,
Wiley EL, Fong SF, Csiszar K, Hendrix MJ and Kirschmann DA: Lysyl
oxidase regulates breast cancer cell migration and adhesion through
a hydrogen peroxide–mediated mechanism. Cancer Res. 65:11429–11436.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kim BR, Dong SM, Seo SH, Lee JH, Lee JM,
Lee SH and Rho SB: Lysyl oxidase-like 2 (LOXL2) controls
tumor-associated cell proliferation through the interaction with
MARCKSL1. Cell Signal. 26:1765–1773. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: an alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Peinado H, Del Carmen Iglesias-de la Cruz
M, Olmeda D, Csiszar K, Fong KS, Vega S, Nieto MA, Cano A and
Portillo F: A molecular role for lysyl oxidase-like 2 enzyme in
snail regulation and tumor progression. EMBO J. 24:3446–3458. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Cuevas EP, Moreno-Bueno G, Canesin G,
Santos V, Portillo F and Cano A: LOXL2 catalytically inactive
mutants mediate epithelial-to-mesenchymal transition. Biol Open.
3:129–137. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wang F, Ruan XJ and Zhang HY: BDE-99
(2,2′,4,4′,5-pentabro-modiphenyl ether) triggers
epithelial-mesenchymal transition in colorectal cancer cells via
PI3K/Akt/Snail signaling pathway. Tumori. 101:238–245. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Lin JJ, Zhao TZ, Cai WK, Yang YX, Sun C,
Zhang Z, Xu YQ, Chang T and Li ZY: Inhibition of histamine receptor
3 suppresses glioblastoma tumor growth, invasion, and
epithelial-to-mesenchymal transition. Oncotarget. 6:17107–17120.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Rafael D, Doktorovová S, Florindo HF,
Gener P, Abasolo I, Schwartz S Jr and Videira MA: EMT blockage
strategies: Targeting Akt dependent mechanisms for breast cancer
metastatic behaviour modulation. Curr Gene Ther. 15:300–312. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
ClinicalTrials.gov: First-in-human study
of AB0024 to evaluate safety and tolerability in adults with
advanced solid tumors. https://clinicaltrials.gov/ct2/show/NCT01323933.
Accessed March 25, 2013.
|
